Under the terms of collaboration, DRL will commercialise Xgeva (denosumab), Vectibix (panitumumab) and Prolia (denosumab) in India, a company statement said today.
In 2015, DRL announced an initial strategic collaboration with Amgen to execute a full range of regulatory and commercial services to seek approval and launch Amgen's Kyprolis (carfilzomib), Blincyto (blinatumomab) and Repatha (evolocumab) in India.
"It strengthens our constant endeavour to enhance patient's access to novel treatment options across therapy areas. These medicines provide unique treatment options to physicians to address unmet medical need in the area of oncology and osteoporosis," said MV Ramana, DRL's Executive Vice President and Head of Emerging markets and India Business.
Xgeva is a Rank ligand (RANKL) inhibitor and is approved in India for the prevention of skeletal related events in patients with advanced malignancies involving bone.
Also Read
Vectibix (panitumumab) is a cancer medication that interferes with the growth and spread of cancer cells in the body.
The scrip of DRL closed at 3151.15, up by 0.31 per cent on the BSE today.
Disclaimer: No Business Standard Journalist was involved in creation of this content